Skip to Content

Exact Sciences Corp EXAS

Morningstar Rating
$59.44 +1.91 (3.32%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Exact Sciences Earnings: Guides In Line With Our View; Progress Suggested on Pipeline and Margins

Exact Science's fourth-quarter results and 2024 guidance were in line with our expectations. The midpoint of the revenue guidance ranges is $2.83 billion for total revenue, $2.165 billion for screening, and $665 million for Precision Oncology, which are year-on-year growth rates of 13%, 16%, and 6%, respectively. We maintain our fair value estimate of $78 per share. The shares are trading at a 14% discount to this, which we view as slightly undervalued.

Price vs Fair Value

EXAS is trading at a 24% discount.
Price
$59.44
Fair Value
$82.00
Uncertainty
Very High
1-Star Price
$954.10
5-Star Price
$78.00
Economic Moat
Hvg
Capital Allocation
Pjlmwwtrh

Bulls Say, Bears Say

Bulls

Cologuard’s staying power is underappreciated. It could take years for liquid biopsy to steal share, and Cologuard’s market share could soar past 10%.

Bears

Exact has yet to reach profitability, and the market is giving the company credit for significant future success despite historical lack of profitability.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EXAS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$57.53
Day Range
$57.1360.56
52-Week Range
$56.05100.77
Bid/Ask
$58.99 / $60.00
Market Cap
$10.79 Bil
Volume/Avg
2.0 Mil / 2.0 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
4.28
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
6,600

Competitors

Valuation

Metric
EXAS
MYGN
GH
Price/Earnings (Normalized)
Price/Book Value
3.432.5514.54
Price/Sales
4.282.443.77
Price/Cash Flow
68.44
Price/Earnings
EXAS
MYGN
GH

Financial Strength

Metric
EXAS
MYGN
GH
Quick Ratio
1.911.646.11
Current Ratio
2.322.016.54
Interest Coverage
−7.26−90.28−198.43
Quick Ratio
EXAS
MYGN
GH

Profitability

Metric
EXAS
MYGN
GH
Return on Assets (Normalized)
−0.51%−1.93%−20.62%
Return on Equity (Normalized)
−1.05%−2.88%−253.35%
Return on Invested Capital (Normalized)
−0.23%−2.33%−25.20%
Return on Assets
EXAS
MYGN
GH
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncKyjpz$219.8 Bil
DHR
Danaher CorpQccndfx$189.3 Bil
IDXX
IDEXX Laboratories IncMbwwz$47.9 Bil
IQV
IQVIA Holdings IncZqqbgx$45.9 Bil
A
Agilent Technologies IncVqbb$40.8 Bil
MTD
Mettler-Toledo International IncCzqfks$27.2 Bil
ICLR
Icon PLCYcpwmsp$26.9 Bil
ILMN
Illumina IncWdsbk$22.3 Bil
WAT
Waters CorpDnn$20.5 Bil
LH
Laboratory Corp of America HoldingsLbpfk$18.3 Bil

Sponsor Center